文章：

间充质干细胞作为胶质瘤治疗载体

Mesenchymal stem cells as therapeutic vehicles for glioma 

原文发布日期：2024-04-23 

英文摘要：

Glioma is a disease with a poor prognosis despite the availability of multimodality treatments, and the development of novel therapies is urgently needed. Challenges in glioma treatment include the difficulty for drugs to cross the blood–brain barrier when administered systemically and poor drug diffusion when administered locally. Mesenchymal stem cells exhibit advantages for glioma therapy because of their ability to pass through the blood–brain barrier and migrate to tumor cells and their tolerance to the immune system. Therefore, mesenchymal stem cells have been explored as vehicles for various therapeutic agents for glioma treatment. Mesenchymal stem cells loaded with chemotherapeutic drugs show improved penetration and tumor accumulation. For gene therapy, mesenchymal stem cells can be used as vehicles for suicide genes, the so-called gene-directed enzyme prodrug therapy. Mesenchymal stem cell-based oncolytic viral therapies have been attempted in recent years to enhance the efficacy of infection against the tumor, viral replication, and distribution of viral particles. Many uncertainties remain regarding the function and behavior of mesenchymal stem cells in gliomas. However, strategies to increase mesenchymal stem cell migration to gliomas may improve the delivery of therapeutic agents and enhance their anti-tumor effects, representing promising potential for patient treatment. 

摘要翻译：

尽管存在多模式治疗方法，胶质瘤仍是一种预后较差的疾病，亟需开发新型疗法。胶质瘤治疗面临的挑战包括：全身给药时药物难以穿过血脑屏障，局部给药时药物扩散性差。间充质干细胞因具备穿过血脑屏障的能力、可迁移至肿瘤细胞的特性以及对免疫系统的耐受性，在胶质瘤治疗中展现出优势。因此，间充质干细胞已被探索作为多种治疗剂的载体用于胶质瘤治疗。负载化疗药物的间充质干细胞表现出更好的穿透性和肿瘤积聚能力。在基因治疗方面，间充质干细胞可作为自杀基因的载体，即所谓的基因导向酶前药疗法。近年来已尝试基于间充质干细胞的溶瘤病毒疗法，以增强对肿瘤的感染效力、病毒复制及病毒颗粒的分布。关于间充质干细胞在胶质瘤中的功能和行为仍存在许多不确定性。然而，提高间充质干细胞向胶质瘤迁移的策略可能会改善治疗剂的递送并增强其抗肿瘤效果，为患者治疗带来潜在希望。

原文链接：

Mesenchymal stem cells as therapeutic vehicles for glioma